PTS-500 is under clinical development by Gongwin Biopharm and currently in Phase II for Malignant Pleural Effusion. According to GlobalData, Phase II drugs for Malignant Pleural Effusion have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PTS-500’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PTS-500 overview
PTS-500 is under development for the treatment of malignant pleural effusion caused due to non small cell lung cancer, lung adenocarcinoma, squamous cell carcinoma and other unspecified lung cancer. The drug candidate is a para-toluene sulfonamide.
Gongwin Biopharm overview
Gongwin Biopharm is a biopharmaceutical company that develops novel anti-cancer drugs. The company utilizes its core technology to develop tumor ablation formulas for companion animals in Taiwan. Its drug product portfolio includes Para-Toluenesulfonamide (PTS), PTS 100, PTS 500, PTS 302, PTS 02, GWA 103, and GWA 106. The company develops drugs to treat lung cancer, tumor cells, liver cancer, hepatocellular carcinoma, adenoid cystic carcinoma, malignant pleural effusion, canine melanoma, breast cancer, and other unspecified cancer diseases. Gongwin Biopharm is headquartered in Taipei City, Taiwan.
For a complete picture of PTS-500’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
